Does elevated intraocular pressure reduce retinal TRKB-mediated survival signaling in experimental glaucoma?
Reduced retrograde transport of neurotrophins (NT) and their receptors has been hypothesized to contribute directly to retinal ganglion cell (RGC) loss in glaucoma. However, strategies of supplementing NT and NT receptors have failed to avert ultimate RGC death in experimental glaucoma. This study examines the response of major components of the NT system and their interacting proteins in a rat glaucoma model. Unilateral chronic intraocular pressure (IOP) elevation was produced by episcleral vein injection of hypertonic saline (N = 99). Retinas were collected and grouped by extent of optic nerve injury. Quantitative reverse transcription PCR, western blot analysis and immunohistochemistry were used to determine mRNA and protein levels and protein localization. Out of three RGC-specific Brn3 proteins (Brn3a, b, and c), only Brn3a was significantly downregulated at the message level to 35 +/- 4% of fellow values with the severest nerve injury. With IOP elevation, no significant alterations were found in retinal mRNA levels for BDNF, NGF, NT-4/5 or NT-3. The abundance of mature retinal BDNF protein was not significantly affected by elevated IOP, while proBDNF protein decreased linearly with increasing injury grade (r(2) = 0.50). In retinas with the severest nerve injury, TrkB and TrkC receptor mRNA levels significantly declined to 67 +/- 9% and 44 +/- 5% of fellow values, respectively. However, the levels of TRKB protein and its phosphorylated form were unchanged. Message level for p75(NTR) was linearly upregulated up to 219 +/- 26% with increasing injury (r(2) = 0.46), but no alteration was detected at protein level. The mRNA expression of p75(NTR) apoptosis adaptor proteins NADE, NRIF, and Lingo1 were significantly downregulated in retinas with the greatest nerve injury. A positive correlation was found between injury extent and message levels for Jun (r(2) = 0.23) as well as Junb (r(2) = 0.27), and RGC labeling of activated JUN protein increased. Atf3 mRNA levels demonstrated a positive linear correlation to the extent of injury (r(2) = 0.53), resulting in a nearly five-fold increase (482 +/- 76%) in eyes with the greatest nerve damage. Among downstream pro-survival signaling components, Erk5 mRNA expression was linearly upregulated (r(2) = 0.32) up to 157 +/- 15% of fellow values in retinas with the severest nerve injury (p < 0.01). A slight positive correlation was found between NF-kappaB message levels and injury extent (r(2) = 0.12). Bcl-xl mRNA levels in the most severely injured retinas were significantly reduced to 83 +/- 7% by elevated IOP exposure. Message levels for Erk1/2, Akt1-3 or Bcl2 appeared unaffected. Elevated IOP did not alter mRNA levels of pro-apoptotic Bim, Bax, or p53. This study demonstrates that elevated IOP exposure does not result in a dramatic decrease in retinal levels of either BDNF or its receptor, TrkB. It shows that the responses of NT pathways to elevated IOP are complex, particularly with regard to the role of p75(NTR) and Atf3. A better understanding of the roles of these proteins in IOP-induced injury is likely to suggest informed strategies for neuroprotection in glaucoma.
Guo
Ying
Y
The Kenneth C. Swan Ocular Neurobiology Laboratory, Casey Eye Institute, Oregon Health and Science University, 3375 SW Terwilliger Blvd, Portland, OR 97239, USA. johnsoel@ohsu.edu
Johnson
Elaine
E
Cepurna
William
W
Jia
Lijun
L
Dyck
Jennifer
J
Morrison
John C
JC
D000818:Animals; D019208:Brain-Derived Neurotrophic Factor / Q000096:biosynthesis / Q000235:genetics; D004195:Disease Models, Animal; D005136:Eye Proteins / Q000096:biosynthesis / Q000235:genetics; D005786:Gene Expression Regulation; D005901:Glaucoma / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology; D007429:Intraocular Pressure / Q000502:physiology; D009414:Nerve Growth Factors / Q000096:biosynthesis / Q000235:genetics; D009419:Nerve Tissue Proteins; D012333:RNA, Messenger / Q000235:genetics; D051381:Rats; D011914:Rats, Inbred BN; D020813:Receptor, trkB / Q000235:genetics / Q000502:physiology*; D017978:Receptors, Growth Factor; D017475:Receptors, Nerve Growth Factor / Q000096:biosynthesis / Q000235:genetics; D012160:Retina / Q000378:metabolism*; D012165:Retinal Ganglion Cells / Q000378:metabolism / Q000473:pathology; D020133:Reverse Transcriptase Polymerase Chain Reaction / Q000379:methods; D015398:Signal Transduction / Q000502:physiology
D019208:Brain-Derived Neurotrophic Factor; D005136:Eye Proteins; D009414:Nerve Growth Factors; D009419:Nerve Tissue Proteins; D012333:RNA, Messenger; D017978:Receptors, Growth Factor; D017475:Receptors, Nerve Growth Factor; C068313:Ngfr protein, rat; D020813:Receptor, trkB
Invest Ophthalmol Vis Sci. 2004 Apr;45(4):1247-58
15037594
Science. 1993 Oct 29;262(5134):695-700
8235590
Neuron. 2003 Jun 19;38(6):899-914
12818176
Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3978-83
9520478
Curr Biol. 2005 Apr 26;15(8):R302-5
15854897
Biochem Biophys Res Commun. 1995 Aug 15;213(2):715-24
7646528
Invest Ophthalmol Vis Sci. 2000 Aug;41(9):2412-21
10937548
Neurosci Lett. 1987 Jul 9;78(1):29-34
3614770
J Biol Chem. 1999 Sep 10;274(37):26563-71
10473620
Eur J Neurosci. 2005 Oct;22(8):1881-94
16262628
Exp Eye Res. 2005 May;80(5):663-70
15862173
Brain Res. 2004 Oct 1;1022(1-2):195-204
15353229
J Neurosci. 2005 Jun 1;25(22):5455-63
15930396
Nat Neurosci. 2001 Oct;4(10):981-8
11544482
Brain Res. 2005 Sep 28;1057(1-2):17-28
16139821
Exp Eye Res. 1997 Jan;64(1):85-96
9093024
Nature. 2004 Feb 26;427(6977):843-8
14985763
Prog Retin Eye Res. 2005 Mar;24(2):217-40
15610974
Brain Res. 2000 Nov 10;883(1):60-8
11063988
Eur J Neurosci. 2004 Jan;19(2):265-72
14725620
Dev Neurobiol. 2007 Jun;67(7):884-94
17506493
Invest Ophthalmol Vis Sci. 2000 Mar;41(3):764-74
10711692
Mol Endocrinol. 1994 Jan;8(1):59-68
8152431
Prog Neurobiol. 2002 Jun;67(3):203-33
12169297
Vision Res. 1998 May;38(10):1517-24
9667016
Invest Ophthalmol Vis Sci. 1994 Mar;35(3):907-15
8125754
Neuron. 2000 Aug;27(2):265-77
10985347
Nat Neurosci. 2004 Mar;7(3):221-8
14966521
Cell Mol Life Sci. 2001 Jul;58(8):1045-53
11529497
J Biol Chem. 1999 Aug 6;274(32):22569-80
10428835
J Cell Sci. 2000 Sep;113 ( Pt 17):3073-84
10934045
Neuroscience. 2008 Feb 6;151(3):771-9
18178318
J Biol Chem. 1997 Apr 4;272(14):8837-40
9082996
J Neurochem. 1997 Jul;69(1):34-42
9202291
Brain Res. 1995 May 15;679(2):249-54
7543356
Invest Ophthalmol Vis Sci. 2004 Jun;45(6):1854-62
15161850
Invest Ophthalmol Vis Sci. 2003 Oct;44(10):4357-65
14507880
Trends Neurosci. 2005 Jan;28(1):5-11
15626491
J Neurobiol. 2004 Feb 15;58(3):341-54
14750147
J Biol Chem. 2004 Feb 6;279(6):4058-65
14617628
J Neurobiol. 1997 Oct;33(4):395-410
9322157
Prog Retin Eye Res. 1999 Jan;18(1):39-57
9920498
Exp Eye Res. 2007 Aug;85(2):250-8
17586494
Neurochem Res. 2005 Sep;30(9):1163-70
16292510
Neuron. 2004 May 27;42(4):529-33
15157416
Mol Vis. 2001 Aug 15;7:192-201
11509915
Invest Ophthalmol Vis Sci. 2008 Jun;49(6):2478-82
18515586
Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):11020-5
10995468
Mol Vis. 2007 Sep 24;13:1783-92
17960131
J Physiol. 2008 Sep 15;586(18):4393-400
18565994
Jpn J Ophthalmol. 2004 Sep-Oct;48(5):460-4
15486768
Annu Rev Biochem. 2003;72:609-42
12676795
Brain Res Mol Brain Res. 1989 Mar;5(2):93-108
2469928
J Neurosci. 2001 Jan 15;21(2):434-43
11160424
Science. 2001 Nov 30;294(5548):1945-8
11729324
Neuron. 1994 Apr;12(4):747-61
8068082
Science. 1999 Nov 12;286(5443):1358-62
10558990
Proc Natl Acad Sci U S A. 1994 Mar 1;91(5):1632-6
8127857
Science. 1995 Nov 24;270(5240):1326-31
7481820
Neuron. 2001 Dec 6;32(5):767-70
11738023
Invest Ophthalmol Vis Sci. 1997 Nov;38(12):2545-53
9375574
Invest Ophthalmol Vis Sci. 2005 Apr;46(4):1313-21
15790897
Invest Ophthalmol Vis Sci. 1995 Apr;36(5):774-86
7706025
Mol Ther. 2005 Sep;12(3):402-12
15975850
J Biosci. 2001 Jun;26(2):179-91
11426054
Curr Eye Res. 1999 Aug;19(2):188-96
10420189
Invest Ophthalmol Vis Sci. 1988 Sep;29(9):1363-71
3417421
J Neurobiol. 2004 Sep 5;60(3):319-27
15281070
Dev Biol. 1989 Dec;136(2):296-303
2573550
Invest Ophthalmol Vis Sci. 2003 Jan;44(1):164-9
12506070
Dev Neurosci. 2007;29(6):438-51
17119319
J Neurosci. 2004 Nov 17;24(46):10521-9
15548667
Exp Eye Res. 2006 Jul;83(1):51-60
16530758
Brain Res. 2004 Jun 11;1011(1):99-106
15140649
Mol Cell Neurosci. 1999 Jul;14(1):28-40
10433815
Invest Ophthalmol Vis Sci. 1996 Mar;37(4):489-500
8595949
Curr Opin Neurobiol. 2005 Feb;15(1):49-57
15721744
Invest Ophthalmol Vis Sci. 2000 May;41(6):1380-5
10798653
Brain Res. 1994 May 30;647(1):30-6
8069702
J Neurosci. 1993 Jun;13(6):2617-26
8501527
Brain Res. 1993 Feb 5;602(2):304-17
8448673
Vision Res. 2002 Jan;42(2):151-7
11809469
J Biol Chem. 1994 Jun 3;269(22):15819-26
7515060
Science. 1996 Apr 26;272(5261):542-5
8614802
J Neurosci. 1986 Oct;6(10):3031-8
2876066
Curr Opin Neurobiol. 2002 Jun;12(3):268-74
12049932
Curr Opin Neurobiol. 2001 Jun;11(3):297-305
11399427
J Neurosci. 1995 Jul;15(7 Pt 1):4762-85
7623109
Vis Neurosci. 2007 Mar-Apr;24(2):127-39
17640403
Invest Ophthalmol Vis Sci. 2009 May;50(5):2194-200
19060281
Mol Ther. 2005 Mar;11(3):373-81
15727933
Neuron. 2000 Sep;27(3):499-512
11055433
Exp Neurol. 2005 Nov;196(1):184-94
16126201
Invest Ophthalmol Vis Sci. 2000 Feb;41(2):431-42
10670473
Dev Biol. 1997 Apr 1;184(1):1-9
9142978
Invest Ophthalmol Vis Sci. 2007 Jul;48(7):3161-77
17591886
Anal Biochem. 1987 Apr;162(1):156-9
2440339
Invest Ophthalmol Vis Sci. 2000 Oct;41(11):3460-6
11006239
J Biol Chem. 1995 May 26;270(21):12665-9
7759517